Overview

Reducing Acute Kidney Injury Occurence by Administering Angiotensin II

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate whether adding angiotensin II to the standard of care is superior compared to the standard of care alone with respect to kidney damage (personalized approach) after cardiac surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Westfälische Wilhelms-Universität Münster
Collaborator:
German Research Foundation
Treatments:
Angiotensin II
Angiotensinogen
Giapreza